PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. REDACTED MATERIAL IS MARKED...Expenditure and Equipment Agreement • May 23rd, 2023 • Indivior PLC • Pharmaceutical preparations
Indivior UK Limited, incorporated and registered under the laws of England and Wales with company number 7183451, having its registered office at The Chapleo Building, Henry Boot Way, Priory Park, Hull HU4 7DY, United Kingdom (“Indivior”).
CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENTExpenditure and Equipment Agreement • March 9th, 2012 • Pozen Inc /Nc • Pharmaceutical preparations • Delaware
THIS CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENT (this “Agreement”) is effective as of December 19, 2011(the “Effective Date”) between
AMENDED AND RESTATED CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENTExpenditure and Equipment Agreement • May 8th, 2013 • Acelrx Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
AMENDED AND RESTATED CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENTExpenditure and Equipment Agreement • May 1st, 2023 • Acelrx Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDED AND RESTATED CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENT (this “Agreement”) is made as of December 12, 2012 (the “Effective Date”) between
